Giacomo Gorini

Before the COVID-19 pandemic, my research focussed on the isolation of human monoclonal antibodies (mAbs) against RH5, a protein expressed by the malaria-causing parasite Plasmodium falciparum which mediates recognition of target red blood cells.

Since the Jenner Institute started its vaccine clinical trial against COVID-19, I have contributed to the study of the vaccine-induced immune response against SARS-CoV-2 through the isolation and characterisation of monoclonal antibodies targeting the viral surface Spike glycoprotein from selected volunteers.

We have set up a high-throughput protocol that allows the isolation of tens of human mAbs against desired antigens, from blood sample to purified product, in a matter of weeks. We are currently working to optimise this protocol for isolation of murine antibodies too.

We are expanding our collaboration network to clone antibodies against a variety of antigens for treatment, research and diagnostic purposes. Collaborations are welcome.